IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control CompletedThis Phase 3 trial tested sibeprenlimab, a drug given as a shot under the skin, in 530 adults with IgA nephropathy, a kidney disease. The study compared the drug to a placebo to see if it could reduce protein in the urine and protect kidney function over time. Participants were a…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody VIS649 tested in humans for first time to fight kidney disease
Disease control CompletedThis early-phase trial tested the safety of a new drug called VIS649 in 51 healthy volunteers. VIS649 is an antibody that blocks a protein called APRIL, which is thought to play a role in IgA nephropathy, a kidney disease. The study gave single doses of the drug or a placebo and …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug shows promise for kidney disease in phase 2 trial
Disease control CompletedThis study tested a new drug called VIS649 in 155 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo, and researchers monitored sid…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for kidney disease in small trial
Disease control CompletedThis study tested whether adding the drug atrasentan to standard care (including SGLT2 inhibitors) can reduce protein in the urine of people with IgA nephropathy, a kidney disease. 54 adults with biopsy-confirmed IgA nephropathy participated. The main goal was to see if atrasenta…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail shows promise for slowing kidney disease
Disease control CompletedThis study tested whether adding sparsentan to a standard SGLT2 inhibitor can better protect kidneys in people with IgA nephropathy, a disease that can lead to kidney failure. 48 adults who were already on stable doses of both a blood pressure drug and an SGLT2 inhibitor took spa…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC